Noise-induced autoimmune sensorineural hearing loss

Annals of Otology, Rhinology and Laryngology

Volumn 112, Issue 7, 2003, Pages 569-573

  Gupta, Reena ^a,c   Sataloff, Robert T ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b GRADUATE HOSPITAL   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune hearing loss; Cytoxan; Immunofluorescence; Imuran; Methotrexate; Noise; Western blot

Indexed keywords

ANTIBODY; AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; FOLIC ACID; HLA DR4 ANTIGEN; METHOTREXATE; METHYLPREDNISOLONE; PLASMA PROTEIN; STEROID;

ADULT; ANAMNESIS; ARTICLE; AUDIOGRAPHY; AUTOIMMUNE DISEASE; CASE REPORT; CLINICAL FEATURE; COMPLEMENT ACTIVATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFICACY; ELECTRONYSTAGMOGRAPHY; ENVIRONMENTAL EXPOSURE; FEMALE; HEARING LOSS; HUMAN; HYPERSENSITIVITY; LABORATORY TEST; LOW DRUG DOSE; NOISE INJURY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTON EMISSION TOMOGRAPHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOM; WESTERN BLOTTING;

EID: 0038503574     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348940311200701     Document Type: Article

References (20)

1. McCabe BF. Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol 1979;88:585-9.
2. Boulassel MR, Deggouj N, Tomasi JP, Gersdorff M. Inner ear autoantibodies and their targets in patients with autoimmune inner ear diseases. Acta Otolaryngol (Stockh) 2001;121:28-34.
3. Veldman JE. Immunology of hearing: experiments of nature. Am J Otol 1989;10:183-7.
4. Hughes GB, Barna BP, Kinney SE, Calabrese LH, Nalepa NJ. Clinical diagnosis of immune inner-ear disease. Laryngoscope 1988;98:251-3.
5. Veldman JE. Cochlear and retrocochlear immune-mediated inner ear disorders. Pathogenetic mechanisms and diagnostic tools. Ann Otol Rhinol Laryngol 1986;95:535-40.
6. Sismanis A, Wise CM, Johnson GD. Methotrexate management of immune-mediated cochleovestibular disorders. Otolaryngol Head Neck Surg 1997;116:146-52.
7. Hoistad DL, Schachern PA, Paparella MM. Autoimmune sensorineural hearing loss: a human temporal bone study. Am J Otolaryngol 1998;19:33-9.
8. Veldman JE, Roord JJ, O'Connor AF, Shea JJ. Autoimmunity and inner ear disorders: an immune-complex mediated sensorineural hearing loss. Laryngoscope 1984;94:501-7.
9. Arnold W. Systemic autoimmune diseases associated with hearing loss. Ann N Y Acad Sci 1997;830:187-202.
10. Harris JP. Autoimmunity of the inner ear. Am J Otol 1989;10:193-5.
11. Ryan AF, Gloddek B, Harris JP. Lymphocyte trafficking to the inner ear. Ann N Y Acad Sci 1997;830:236-42.
12. Lasak JM, Sataloff RT, Hawkshaw M, Carey TE, Lyons KM, Spiegel JR. Autoimmune inner ear disease: steroid and cytotoxic drug therapy. Ear Nose Throat J 2001;80:808-11, 815-6, 818.
13. Hirose K, Wener MH, Duckert LG. Utility of laboratory testing in autoimmune inner ear disease. Laryngoscope 1999;109:1749-54.
14. Carey TE, Nair TS, Gray JP, et al. The search for the inner ear antigen of autoimmune sensorineural hearing loss. In: Veldman JE, Passali D, Lim DJ, eds. New frontiers in immunobiology. The Hague, the Netherlands: Kugler, 1999:67-74.
15. Harris JP, Ryan AF. Fundamental immune mechanisms of the brain and inner ear. Otolaryngol Head Neck Surg 1995;112:639-53.
16. Clements PJ. Alkylating agents. In: Dixon J, Furst DE, eds. Second line agents in the treatment of rheumatic diseases. New York, NY: Marcel Dekker, 1991:335-61.
17. Songsiridej N, Furst DE. Methotrexate - the rapidly acting drug. Baillieres Clin Rheumatol 1990;4:575-93.
18. Matteson EL, Tirzaman O, Facer GW, et al. Use of methotrexate for autoimmune hearing loss. Ann Otol Rhinol Laryngol 2000;109:710-4.
19. Salley LH Jr, Grimm M, Sismanis A, Spencer RF, Wise CM. Methotrexate in the management of immune mediated cochleovestibular disorders: clinical experience with 53 patients. J Rheumatol 2001;28:1037-40.
20. Sismanis A, Thompson T, Willis HE. Methotrexate therapy for autoimmune hearing loss: a preliminary report. Laryngoscope 1994;104:932-4.